	US 12,454,554 B2
	Influenza virus vaccines and uses thereof
Mandy Antonia Catharina Jongeneelen, Leiden (NL); Tina Ritschel, Oegstgeest (NL); Ferdinand Jacobus Milder, Zwolle (NL); Indigo King, Seattle, WA (US); Yifan Song, Seattle, WA (US); Johannes Petrus Maria Langedijk, Amsterdam (NL); and Boerries Brandenburg, Utrecht (NL)
Assigned to Janssen Vaccines & Prevention B.V., Leiden (NL)
Appl. No. 17/753,506
Filed by JANSSEN VACCINES & PREVENTION B.V., Leiden (NL)
PCT Filed Sep. 3, 2020, PCT No. PCT/EP2020/074539 § 371(c)(1), (2) Date Mar. 4, 2022, PCT Pub. No. WO2021/043869, PCT Pub. Date Mar. 11, 2021.
Claims priority of provisional application 62/896,244, filed on Sep. 5, 2019.
Prior Publication US 2023/0250135 A1, Aug. 10, 2023
Int. Cl. A61K 39/00 (2006.01); A61K 39/145 (2006.01); A61P 31/16 (2006.01); C07K 14/005 (2006.01); C07K 14/11 (2006.01)

CPC C07K 14/005 (2013.01) [A61P 31/16 (2018.01); A61K 39/00 (2013.01); C07K 2319/42 (2013.01)]

25 Claims

1. A monomeric influenza A hemagglutinin (HA) stem polypeptide, comprising an HA1 and a HA2 domain of an HA of a group 2 influenza A virus, said HA stem polypeptide comprising an amino acid sequence which comprises:

a deletion of the head region from the HA1 domain;

a modification of the trimerization region in the HA2 domain;

at least two cysteine residues capable of forming at least one intramonomeric cysteine bridge;

and wherein in the amino acid sequence the amino acid at position 355 is W, wherein the numbering of the amino acid positions in the HA stem polypeptide amino acid sequence is H3 numbering corresponding to the full-length HA numbering of the reference strain H3N2 A/Aichi/2/68 (SEQ ID NO: 1).